Antibacterial composition against malassezia pachydermatis

Abstract

The present invention relates to an antibacterial composition against Malassezia pachydermatis, the composition comprising at least two selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylylglycol. The antibacterial composition has an antibacterial synergistic effect by a combination of specific components, and thus can be applied to products for preventing or alleviating diseases caused by Malassezia pachydermatis.

Description

Antibacterial composition against Malassezia patchermatis

[0001] It relates to an antibacterial composition against Malassezia pachydermatis.

[0002] Malassezia is a genus of fungi belonging to the Basidiomycota, and 15 species have been identified to date. Of these, 10 species (M. restricta, M. globosa, M. furfur, M. sympodialis, M. obtusa, M. slooffiae, M. japonica, M. yamatoensis, M. dermatis, M. arunalokei) are considered to be human-friendly. In addition to the above species, 5 species (M. pachydermatis, M. cuniculi, M. caprae, M. equine, M. nana) are mainly isolated from livestock or companion animals. In particular, M. pachydermatis is mainly observed in companion dogs and cats, and is also known as a fungus that causes dermatitis and otitis externa in companion dogs. Malassezia patchydermatis lives on the skin of dogs and cats. While it doesn't pose a significant problem when your pet is healthy, it can cause skin problems when the fungus proliferates in humid environments, due to allergies or a weakened immune system.

[0003] Therefore, in order to prevent or improve skin diseases in companion animals, it is necessary to develop an antibacterial agent against Malassezia patchdermatis.

[0004] One aspect is to provide an antibacterial composition against Malassezia pachydermatis, comprising two or more selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol.

[0005] Another aspect is to provide a cosmetic composition comprising the above antibacterial composition.

[0006] Another aspect is to provide a pharmaceutical composition for preventing or improving a disease caused by Malassezia pachydermatis, comprising the above antibacterial composition.

[0007] Another aspect provides a method for preventing or ameliorating a disease caused by Malassezia patchdermatis, comprising administering to a subject an effective amount of the antimicrobial composition.

[0008] Another aspect provides a use of the antimicrobial composition for preparing a medicament for preventing or ameliorating a disease caused by Malassezia patchdermatis.

[0009] One aspect provides an antibacterial composition against Malassezia pachydermatis, comprising two or more selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol.

[0010] An antimicrobial composition according to one aspect may exhibit a synergistic antimicrobial effect against Malassezia pachydermatis by including a combination of specific ingredients.

[0011] The above antibacterial composition may include two or three selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol.

[0012] In one embodiment, the antimicrobial composition may comprise a combination of ingredients selected from the following:

[0013] (1) 1,2-hexanediol and ethylhexylglycerin;

[0014] (2) 1,3-propanediol and hydroxyacetophenone;

[0015] (3) 1,3-propanediol and ethylhexylglycerin;

[0016] (4) Caprylyl glycol and hydroxyacetophenone;

[0017] (5) Caprylyl glycol and ethylhexylglycerin;

[0018] (6) 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin;

[0019] (7) caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone; and

[0020] (8) Caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin.

[0021] In the above combination (1), the concentration ratio of 1,2-hexanediol and ethylhexylglycerin may be 1 to 32:1, 1 to 8:1, 1 to 4:1, or 1 to 2:1. In a specific embodiment, the concentration ratio of 1,2-hexanediol and ethylhexylglycerin may be any range or any value selected from the range of 1 to 32:1. For example, the concentration ratio of 1,2-hexanediol and ethylhexylglycerin may be 1:1, 2:1, 4:1, 8:1, or 32:1. In the above concentration ratio range, 1,2-hexanediol and ethylhexylglycerin may exhibit a partial antibacterial synergistic effect against Malassezia patchdermatis. When the concentration ratio of 1,2-hexanediol and ethylhexylglycerin is more than 32:1, the FICI judgment may be 'no antibacterial synergy effect' due to the increase in the 1,2-hexanediol content; when it is less than 1:1, there may be no antibacterial effect due to the decrease in the 1,2-hexanediol content and the proliferation of microorganisms.

[0022] In the above combination (2), the concentration ratio of 1,3-propanediol and hydroxyacetophenone may be 0.25 to 4:1, 1 to 4:1 to 4, 1:1 to 4, 1 to 4:1, 2 to 4:1, 1:2 to 4, 1:1 to 2, or 1 to 2:1. In a specific embodiment, the concentration ratio of 1,3-propanediol and hydroxyacetophenone may be any range or any value selected from the range of 1 to 4:1 to 4. In certain embodiments, the concentration ratio of 1,3-propanediol and hydroxyacetophenone can be any range or any value selected from the range of 0.25 to 4:1. For example, the concentration ratio of 1,3-propanediol and hydroxyacetophenone can be 4:1, 2:1, 1:1, 1:2 (0.5:1), or 1:4 (0.25:1). In the concentration ratio range of 2 to 4:1, 1,3-propanediol and hydroxyacetophenone can exhibit partial antibacterial synergistic effect against Malassezia patchdermatis. In the concentration ratio range of 1:1 to 4, 1,3-propanediol and hydroxyacetophenone can exhibit antibacterial synergistic effect against Malassezia patchdermatis. When the concentration ratio of 1,3-propanediol and hydroxyacetophenone is more than 4:1, the FICI judgment may be 'no antibacterial synergy effect' due to the increase in 1,3-propanediol content; when it is less than 1:4 (less than 0.25:1), there may be no antibacterial effect due to the decrease in 1,3-propanediol content and microbial growth.

[0023] In the above combination (3), the concentration ratio of 1,3-propanediol and ethylhexylglycerin may be 2 to 8:1, 2 to 4:1, or 4 to 8:1. In a specific embodiment, the concentration ratio of 1,3-propanediol and ethylhexylglycerin may be any range or any value selected from the range of 2 to 8:1. For example, the concentration ratio of 1,3-propanediol and ethylhexylglycerin may be 2:1 or 8:1. In the above concentration ratio range, 1,3-propanediol and ethylhexylglycerin may exhibit a partial antibacterial synergistic effect against Malassezia patchdermatis. When the concentration ratio of 1,3-propanediol and ethylhexylglycerin is more than 8:1, the FICI judgment may be 'no antibacterial synergy effect' due to the increase in 1,3-propanediol content; when it is less than 2:1, there may be no antibacterial effect due to the decrease in 1,3-propanediol content and microbial growth.

[0024] In the above combination (4), the concentration ratio of caprylyl glycol and hydroxyacetophenone may be 1 to 4:1, 1 to 3:1, 1 to 2.5:1, 1 to 2:1, or 1 to 1.5:1. In a specific embodiment, the concentration ratio of caprylyl glycol and hydroxyacetophenone may be any range or any value selected from the range of 1 to 2:1. For example, the concentration ratio of caprylyl glycol and hydroxyacetophenone may be 1:1 or 2:1. In the above concentration ratio range, caprylyl glycol and hydroxyacetophenone may exhibit a partial antibacterial synergistic effect against Malassezia patchdermatis. When the concentration ratio of caprylyl glycol and hydroxyacetophenone is more than 4:1, there may be no antibacterial effect due to a decrease in the content of hydroxyacetophenone and microbial growth; when it is less than 1:1, the FICI judgment may be 'no antibacterial synergy effect' due to an increase in the content of hydroxyacetophenone.

[0025] In the above combination (5), the concentration ratio of caprylyl glycol and ethylhexylglycerin may be 0.25 to 4:1, 0.25 to 2:1, 1 to 2:1 to 4, 1 to 2:1, 1:1 to 4, or 1:2 to 4. In a specific embodiment, the concentration ratio of caprylyl glycol and ethylhexylglycerin may be any range or any value selected from the range of 1 to 2:1 to 4. In a specific embodiment, the concentration ratio of caprylyl glycol and ethylhexylglycerin may be any range or any value selected from the range of 0.25 to 2:1. For example, the concentration ratio of caprylyl glycol and ethylhexylglycerin may be 2:1, 1:2 (0.5:1), or 1:4 (0.25:1). Within the above concentration ratio range, caprylyl glycol and ethylhexylglycerin may exhibit a partial antibacterial synergistic effect against Malassezia patchdermatis. When the concentration ratio of caprylyl glycol and ethylhexylglycerin is greater than 4:1, the FICI evaluation may be 'no antibacterial synergistic effect' due to the increase in the caprylyl glycol content; and when it is less than 1:4 (less than 0.25:1), the antibacterial effect may be absent due to the decrease in the caprylyl glycol content and the proliferation of microorganisms.

[0026] In the above combination (6), the concentration ratio of 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin may be 8 to 32:2 to 8:1, 10 to 30:3 to 7:1, 10 to 20:3 to 6:1, 14 to 18:3 to 5:1, or 15 to 17:3 to 5:1. In a specific embodiment, the concentration ratio of 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin may be any range or any value selected from the range of 8 to 32:2 to 8:1. For example, the concentration ratio of 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin may be 16:4:1. Within the above concentration range, 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin may exhibit partial antibacterial synergistic effects against Malassezia patchdermatis. Beyond the above concentration range, the FICI may determine "no antibacterial synergistic effect" or "antagonistic effect," or the antibacterial effect may be absent due to microbial proliferation.

[0027] In the above combination (7), the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone may be 1:0.5 to 16:1 to 8, 1 to 2:1 to 16:1 to 8, 1:1 to 16:1 to 8, 1 to 2:1:2 to 4, 1:2 to 4:1, or 1:1 to 2:1. In a specific embodiment, the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone may be any range or any value selected from the range of 1 to 2:1 to 16:1 to 8. In certain embodiments, the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone can be any range or any value selected from the range of 1:0.5 to 16:1 to 8. For example, the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone can be 1:4:8, 1:4:2, 1:2:2, 1:1:2, 2:1:4 (1:0.5:2), 1:4:1, 1:16:2, or 1:2:1. Caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone can exhibit partial antibacterial synergistic effect or antibacterial synergistic effect against Malassezia patchdermatis at a concentration ratio of 1 to 2:1 to 16:1 to 8 or 1:0.5 to 16:1 to 8. Caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone can exhibit antibacterial synergistic effect against Malassezia patchdermatis at a concentration ratio of 1:2:1. When the concentration ratio is out of the above range, the FICI judgment may be 'no antibacterial synergistic effect' or 'antagonistic effect', or there may be no antibacterial effect due to microbial proliferation.

[0028] In the above combination (8), the concentration ratio of caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin may be 2 to 8:8 to 16:1, 2 to 4:8 to 16:1, 4 to 8:8 to 16:1, or 2 to 8:16:1. In a specific embodiment, the concentration ratio of caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin may be any range or any value selected from the range of 2 to 8:8 to 16:1. For example, the concentration ratio of caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin may be 4:8:1, 2:16:1, or 8:16:1. At the above concentration ratio, caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin may exhibit a partial antibacterial synergistic effect against Malassezia patchdermatis. If the concentration ratio is outside the above range, the FICI may determine "no antibacterial synergistic effect" or "antagonistic effect," or the antibacterial effect may be absent due to microbial proliferation.

[0029] In certain embodiments, the antimicrobial composition may exhibit a partial antimicrobial synergistic effect or an antimicrobial synergistic effect against Malassezia patchdermatis at the following combinations and concentration ratios of ingredients:

[0030] (1) An antibacterial composition having a concentration ratio of 1,2-hexanediol and ethylhexylglycerin of 1 to 32:1;

[0031] (2) An antibacterial composition having a concentration ratio of 1,3-propanediol and hydroxyacetophenone of 0.25 to 4:1;

[0032] (3) An antibacterial composition having a concentration ratio of 1,3-propanediol and ethylhexylglycerin of 2 to 8:1;

[0033] (4) An antibacterial composition having a concentration ratio of caprylyl glycol and hydroxyacetophenone of 1 to 2:1;

[0034] (5) An antibacterial composition having a concentration ratio of caprylyl glycol and ethylhexylglycerin of 0.25 to 2:1;

[0035] (6) An antibacterial composition in which the concentration ratio of 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin is 8 to 32:2 to 8:1, or 16:4:1;

[0036] (7) An antibacterial composition having a concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone of 1:0.5 to 16:1 to 8; or

[0037] (8) An antibacterial composition in which the concentration ratio of caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin is 2 to 8:8 to 16:1.

[0038] In certain embodiments, the antimicrobial composition may exhibit excellent antimicrobial synergy effects against Malassezia patchdermatis at the following combinations and concentration ratios of ingredients:

[0039] (2) An antibacterial composition having a concentration ratio of 1,3-propanediol and hydroxyacetophenone of 1:1 to 4; or

[0040] (7) An antibacterial composition in which the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone is 1:1 to 2:1, or 1:2:1.

[0041] In the above antibacterial composition, the concentration of the 1,2-hexanediol may be any range or any value selected from the range of 0.1% (w / w) to 3% (w / w). For example, the concentration of the 1,2-hexanediol may be 0.125% (w / w) to 2% (w / w).

[0042] In the above antibacterial composition, the concentration of ethylhexylglycerin may be any range or any value selected from the range of 0.01% (w / w) to 0.3% (w / w). For example, the concentration of ethylhexylglycerin may be 0.015625% (w / w) to 0.125% (w / w).

[0043] In the above antibacterial composition, the concentration of the 1,3-propanediol may be any range or any value selected from the range of 0.03% (w / w) to 1% (w / w). For example, the concentration of the 1,3-propanediol may be 0.03125% (w / w) to 0.5% (w / w).

[0044] In the above antibacterial composition, the concentration of the hydroxyacetophenone may be any range or any value selected from the range of 0.05% (w / w) to 0.5% (w / w). For example, the concentration of the hydroxyacetophenone may be 0.0625% (w / w) to 0.25% (w / w).

[0045] In the above antibacterial composition, the concentration of caprylyl glycol may be any range or any value selected from the range of 0.03% (w / w) to 0.3% (w / w). For example, the concentration of caprylyl glycol may be 0.03125% (w / w) to 0.125% (w / w).

[0046] The above antibacterial composition can exhibit an antibacterial synergistic effect against Malassezia pachydermatis.

[0047] The above Malassezia pachydermatis is known as a fungus that causes various diseases in mammals such as humans, dogs, and cats. The above Malassezia pachydermatis can cause inflammatory diseases in the skin, ears, scalp, mucosal surfaces (e.g., mouth, anus, vagina), etc. Therefore, an antibacterial composition for Malassezia pachydermatis can be used for the prevention or improvement of Malassezia patchdermatis infection or diseases caused by Malassezia patchdermatis.

[0048] Another aspect provides a cosmetic composition comprising the antibacterial composition.

[0049] The above cosmetic composition may additionally include ingredients commonly used in cosmetic compositions, functional additives, etc., and may include conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, fragrances, etc., and carriers.

[0050] The above cosmetic composition is not particularly limited to a specific formulation, and the formulation can be appropriately selected depending on the purpose. The cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersion formulation. The cosmetic composition may have, for example, a toner, a cream, an essence, a cleansing foam, cleansing water, a pack, an ampoule, a body lotion, a body oil, a body gel, a shampoo, a rinse, a hair conditioner, a hair gel, a foundation, a lipstick, a mascara, a makeup base, or a cosmetic formulation of a skin-adhesive type. The cosmetic formulation of a skin-adhesive type may be, for example, a mask pack, but is not limited thereto.

[0051] The above cosmetic composition may be for use in companion animals. The cosmetic composition may be for use in companion animal skin care, companion animal scalp care, or companion animal hair care. The companion animal may include, but is not limited to, dogs, cats, etc.

[0052] The cosmetic composition may have a formulation suitable for application to companion animals. The cosmetic composition may be, but is not limited to, a body wash, shampoo, or rinse for companion animals.

[0053] Alternatively, the cosmetic composition may be a composition for external application to the skin. Specifically, it may be a composition for external application to the skin of a companion animal.

[0054] The above-mentioned external preparation for skin may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The above-mentioned external preparation for skin may be appropriately mixed with ingredients commonly used in external preparations for skin such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, metal ion sequestrants, sugars, or a combination thereof, as needed.

[0055] Another aspect provides a pharmaceutical composition for preventing or improving a disease caused by Malassezia pachydermatis, comprising the above antibacterial composition.

[0056] The above "disease caused by Malassezia patchdermatis" may be used interchangeably with "Malassezia patchdermatis infection" and may specifically include inflammatory diseases of the skin, ears, scalp, mucosal surfaces (e.g., oral cavity, anus, vagina), etc., caused by Malassezia patchdermatis, including, but not limited to, dermatitis, otitis externa, pruritus, tinea versicolor (ringworm), dandruff, etc. The term may also include allergic reactions and pyoderma, skin pigmentation, lichenification, etc. caused by Malassezia patchdermatis in companion animals.

[0057] The term "prevention" encompasses suppressing the onset of a disease. The term "treatment" encompasses suppressing, alleviating, or eliminating the development of a disease. The term "improvement" can refer to any action that at least reduces the severity of symptoms, such as parameters associated with alleviating or curing a condition.

[0058] The pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a glidant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium dihydrogen phosphate anhydrous, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, or a combination thereof. The glidant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

[0059] The above pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may include granules, powders, liquids, tablets, capsules, dry syrups, etc. Parenteral dosage forms may include injections, ointments, etc.

[0060] Another aspect provides a method for preventing or ameliorating a disease caused by Malassezia patchdermatis, comprising administering to a subject an effective amount of the antimicrobial composition.

[0061] The term "effective amount" means an amount effective enough to produce the effect mentioned above.

[0062] As used herein, the terms "administering," "introducing," and "implanting" are used interchangeably and may refer to placement of a composition according to an embodiment into a subject by a method or route that results in at least partial localization of the composition to a desired site according to an embodiment.

[0063] The subject may be an individual in need of prevention or improvement of a disease caused by Malassezia patchdermatis. The subject may be a mammal, including a human, a dog, a cat, or the like. For example, the subject may be a companion animal. The companion animal may be a dog or a cat.

[0064] Administration may be by any method known in the art. The route of administration, frequency of administration, and other administration methods can be appropriately selected by those skilled in the art. Administration may be administered directly to a subject by any means, including intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. Administration may be systemic or local. Administration may include application to the skin.

[0065] The above administration may be 0.1 mg to 1,000 mg of the composition according to one specific example per subject per day, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may vary depending on factors such as the formulation method, administration method, patient age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and those skilled in the art can appropriately adjust the dosage by considering these factors. The frequency of administration may be once a day or twice or more within the range of clinically acceptable side effects. Regarding the site of administration, it may be administered to one or more sites, and the total number of days of administration may be from 1 to 30 days per treatment, daily or at intervals of 2 to 5 days. If necessary, the same treatment may be repeated after an appropriate period.

[0066] Another aspect provides the use of the antimicrobial composition for preparing a medicament for preventing or ameliorating a disease caused by Malassezia patchdermatis.

[0067] Duplicate content is omitted in consideration of the complexity of this specification, and terms not otherwise defined herein have the meanings commonly used in the technical field to which the present invention belongs.

[0068] An antimicrobial composition according to one aspect has an antimicrobial synergistic effect against Malassezia patchdermatis by including a combination of specific ingredients selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol. Therefore, the antimicrobial composition can be applied to products for preventing or improving diseases caused by Malassezia patchdermatis.

[0069] The following examples are provided for more detailed description. However, these examples are provided solely to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.

[0070] Example 1: Evaluation of antibacterial activity against Malassezia patchermatis

[0071] The antibacterial activity of two or three combinations of 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol against Malassezia pachydermatis was evaluated.

[0072] The calculation method for FIC (Fractional Inhibiting Concentration) is as shown in Table 1 below.

[0073]

[0074] The method for determining the FIC Index (FICI) is as shown in Table 2 below.

[0075]

[0076] The FICI evaluation results for each ingredient combination are shown in Tables 3 to 10 below.

[0077] <Abbreviation>

[0078] 1,2-HD: 1,2-Hexanediol

[0079] EHG: Ethylhexylglycerine

[0080] 1,3-PD: 1,3-Propanediol

[0081] HAP: Hydroxyacetophenone

[0082] CG: Caprylyl Glycol

[0083]

[0084] As shown in Table 3 above, it was confirmed that 1,2-hexanediol and ethylhexylglycerin exhibited a partial antibacterial synergy effect at a concentration ratio of 1 to 32:1.

[0085]

[0086] As shown in Table 4 above, 1,3-propanediol and hydroxyacetophenone were confirmed to exhibit partial or antibacterial synergy effects at a concentration ratio of 1 to 4: 1 to 4. In particular, it was confirmed to exhibit an excellent antibacterial synergy effect at a concentration ratio of 1: 1 to 4.

[0087]

[0088] As shown in Table 5 above, it was confirmed that 1,3-propanediol and ethylhexylglycerin exhibited a partial antibacterial synergy effect at a concentration ratio of 2 to 8:1.

[0089]

[0090] As shown in Table 6 above, it was confirmed that caprylyl glycol and hydroxyacetophenone exhibited a partial antibacterial synergy effect at a concentration ratio of 1 to 2:1.

[0091]

[0092] As shown in Table 7 above, it was confirmed that caprylyl glycol and ethylhexylglycerin exhibited a partial antibacterial synergy effect at a concentration ratio of 1 to 2: 1 to 4.

[0093]

[0094] As shown in Table 8 above, it was confirmed that 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin exhibited a partial antibacterial synergy effect at a concentration ratio of 16:4:1.

[0095]

[0096] As shown in Table 9 above, it was confirmed that caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone exhibited partial or antibacterial synergy effects at concentration ratios of 1 to 2:1 to 16:1 to 8. In particular, it was confirmed that a very excellent antibacterial synergy effect was exhibited at a concentration ratio of 1:2:1.

[0097]

[0098] As shown in Table 10 above, it was confirmed that caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin exhibited partial antibacterial synergy at concentration ratios of 2 to 8:8 to 16:1. In summary, it was confirmed that a specific combination of the five components of 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol had an antibacterial synergistic effect against Malassezia pachydermatis.

Claims

An antibacterial composition against Malassezia pachydermatis, comprising two or more selected from 1.1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol.

2. An antibacterial composition according to claim 1, comprising two or three selected from 1,2-hexanediol, ethylhexylglycerin, 1,3-propanediol, hydroxyacetophenone, and caprylyl glycol.

3. An antibacterial composition according to claim 1, comprising a combination of components selected from the following: (1) 1,2-hexanediol and ethylhexylglycerin; (2) 1,3-propanediol and hydroxyacetophenone; (3) 1,3-propanediol and ethylhexylglycerin; (4) Caprylyl glycol and hydroxyacetophenone; (5) Caprylyl glycol and ethylhexylglycerin; (6) 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin; (7) caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone; and (8) Caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin.

4. In claim 3, (1) The concentration ratio of 1,2-hexanediol and ethylhexylglycerin is 1 to 32:1; (2) The concentration ratio of 1,3-propanediol and hydroxyacetophenone is 0.25 to 4:1; (3) The concentration ratio of 1,3-propanediol and ethylhexylglycerin is 2 to 8:1; (4) The concentration ratio of caprylyl glycol and hydroxyacetophenone is 1 to 4:1; (5) The concentration ratio of caprylyl glycol and ethylhexylglycerin is 0.25 to 4:1; (6) The concentration ratio of 1,2-hexanediol, 1,3-propanediol, and ethylhexylglycerin is 8 to 32:2 to 8:1; (7) The concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone is 1:0.5 to 16:1 to 8; (8) An antibacterial composition wherein the concentration ratio of caprylyl glycol, 1,3-propanediol, and ethylhexylglycerin is 2 to 8:8 to 16:

1.

5. In claim 4, (2) The concentration ratio of 1,3-propanediol and hydroxyacetophenone is 1:1 to 4; (7) An antibacterial composition wherein the concentration ratio of caprylyl glycol, 1,3-propanediol, and hydroxyacetophenone is 1:1 to 2:

1.

6. In claim 1, The concentration of the above 1,2-hexanediol is 0.1% (w / w) to 3% (w / w), The concentration of the above ethylhexylglycerin is 0.01% (w / w) to 0.3% (w / w), The concentration of the above 1,3-propanediol is 0.03% (w / w) to 1% (w / w), The concentration of the above hydroxyacetophenone is 0.05% (w / w) to 0.5% (w / w), An antibacterial composition wherein the concentration of the caprylyl glycol is 0.03% (w / w) to 0.3% (w / w).

7. In claim 1, The concentration of the above 1,2-hexanediol is 0.125% (w / w) to 2% (w / w), The concentration of the above ethylhexylglycerin is 0.015625% (w / w) to 0.125% (w / w), The concentration of the above 1,3-propanediol is 0.03125% (w / w) to 0.5% (w / w), The concentration of the above hydroxyacetophenone is 0.0625% (w / w) to 0.25% (w / w), An antibacterial composition wherein the concentration of the caprylyl glycol is 0.03125% (w / w) to 0.125% (w / w).

8. A cosmetic composition comprising the antibacterial composition of claim 1.

9. A cosmetic composition for use in companion animals according to claim 8.

10. A pharmaceutical composition for preventing or improving a disease caused by Malassezia pachydermatis, comprising the antibacterial composition of claim 1.

Images